Skip to main content
Premium Trial:

Request an Annual Quote

Gene Logic to Reposition Drugs for Eli Lilly

NEW YORK (GenomeWeb News) – Gene Logic today said it will try to discover new development paths for drug candidates discontinued in clinical trials by Eli Lilly.
 
The candidates were discontinued for reasons other than safety, Gene Logic said.
 
Under the deal, Gene Logic has the option to receive an exclusive license to any drug candidate Eli Lilly decides not to purse. Eli Lilly would receive success-based milestone and royalty payments on those candidates.
 
The milestone payments and royalties under the agreement are similar to those in development-stage in-licensing deals, Gene Logic said. The payments are discounted because Eli Lilly originated the compound.
 
Gene Logic has similar agreements with Pfizer, Roche, and Organon.
 
Additional details were not disclosed.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.